Ocumetra’s product portfolio comprises nine clinical tools, including interactive ocular growth charts, myopia treatment efficacy analytics, risk indicators and other clinical decision support tools, such as the Refractogram. The Refractogram makes advanced myopia treatment accessible to all, providing evidence-based, detailed graphical and numerical indicators of treatment efficacy. It allows therapy decisions to be optimised and care benefits to be demonstrated to every patient.
“Ocuco sees myopia control as a key opportunity for the industry, and we see our role as providing tools to support ECPs deliver myopia control to their patients. Integrating Ocumetra’s clinical tools into our next-generation PMS brings the clinical support that ECPs need to support this new area within their practice management and EMR system, “explains Leo Mac Canna, Ocuco CEO.
Ocumetra was founded in 2020 by Professor James Loughman and Professor Ian Flitcroft. The data science company aims to deliver personalised myopia care solutions and vital decision support to practitioners in this rapidly changing field of clinical practice. According to James Loughman, Ocumetra’s clinical tools were built based on information from over one million eyes from all over the world. Consequently, its machine learning solutions are suitable for eyecare professionals worldwide.
James Loughman, an Optometrist with more than 20 years of clinical, academic, research and management experience and Clinical Research Director for Ocuco, explains that the partnership with the optical software provider was natural. “This exciting collaboration will allow us to integrate our suite of clinical decision support and patient communication tools within Ocuco’s PMS. Ocumetra’s technology converts the clinical records of each patient stored in Ocuco’s PMS and EMR systems into intuitive infographic outputs, providing personalised and evidence-based treatment information for every patient,” details Loughman.
According to co-founder Ian Flitcroft, a leading Ophthalmologist in the field of myopia management, these tools will guide clinical decision-making and simplify and shorten the treatment conversation with patients at every stage of the myopia care pathway. Overall, Ocumetra’s tools will reduce chair time, improve treatment uptake and retention and ultimately help achieve better health outcomes for patients.
Some of Ocumetra’s products will launch early in 2022. Additional products are considered software as a medical device and are subject to regulatory requirements. Hence the company is already working to advance along the regulatory pathway towards ISO13485 accreditation, CE mark acquisition and Food and Drug Administration (FDA) approval.